| Powder: | Yes |
|---|---|
| Customized: | Non-Customized |
| Suitable for: | Adult |
| Purity: | >98% |
| Color: | White |
| Grade: | Pharmaceutical Grade |
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier | Chemical Name: | Sotorasib |
| Molecular Formula: | C30H30F2N6O3 |
| Formula Weight: | 560.59 |
| CAS No.: | 2252403-56-6 |
Sotorasib (AMG 510) is being developed by Amgen. Phase 1 clinical trials were completed in late 2020. In December 2019, it was approved to begin Phase 2 clinical trials.
Because the G12C KRAS mutation is relatively common in some cancer types, 14% of non-small-cell lung cancer adenocarcinoma patients and 5% of colorectal cancer patients, and sotorasib is the first drug candidate to target this mutation, there have been high expectations for the drug.The Food and Drug Administration has granted a fast track designation to sotorasib for the treatment of metastatic non-small-cell lung carcinoma with the G12C KRAS mutation.
AMG-510 is a KRAS G12C inhibitor. Because it interrupts protein signaling, it causes KRAS G12C tumor regression.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}